# Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

> **NCT00970177** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 812 (actual)

## Conditions studied

- Pandemic Influenza

## Interventions

- **BIOLOGICAL:** Monovalent A/H1N1 influenza vaccine

## Key facts

- **NCT ID:** NCT00970177
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2009-10
- **Final completion:** 2011-03
- **Target enrollment:** 812 (ACTUAL)
- **Last updated:** 2016-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00970177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00970177, "Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00970177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*